John A. Galloway

Last updated

John A. Galloway (born December 8, 1928) is an endocrinologist who has made major contributions to the study and treatment of diabetes. He was clinical research fellow and principal physician in charge of diabetes-related research at the Lilly Laboratory for Clinical Research. The holder of four patents and author of over 80 publications, Galloway also served as Professor of Medicine at the Indiana University School of Medicine.

Contents

Education

Galloway was born in Omaha, Nebraska. He received a Bachelor of Arts degree from the University of Pennsylvania in 1950. After completing Reserve Officers' Training Corps program, he was commissioned in August, 1950, serving in the U.S. Army, including combat in Korea. He was released in August, 1952, to go to medical school, and graduated in 1956, from the University of Nebraska College of Medicine. He did his internship at Nebraska Methodist Hospital in Omaha and his residency in internal medicine at Temple University Hospital in Philadelphia. During his last year, he was the chief medical resident. He was then a fellow and instructor in endocrinology and diabetes at Temple, 1960-61.

Career

For nineteen years, Galloway was the principal physician in charge of diabetes-related research at the Lilly Laboratory for Clinical Research at the Wishard Memorial Hospital, at Indiana University School of Medicine.

In December 1993, Galloway retired from the Lilly Research Laboratories. At his retirement he was clinical research fellow, an executive-director-level position. From 1994-97, he was a part-time consultant to the Lilly diabetes research and diabetes care divisions. He continued to consult for pharmaceutical companies and other research institutions on diabetes research and treatment through 1997.

Galloway was also director of the diabetic clinic at Wishard, the principal primary care hospital in Indianapolis for indigent patients and for patients from the Veterans Administration Hospital in Indianapolis. He then served as a senior consultant to that unit, until December 1996.

Memberships and Affiliations

Galloway is a Fellow of the American College of Physicians, certified by the American Board of Internal Medicine, a member of the Massachusetts Medical Society] the Collier County Medical Society and the Florida Medical Association. A member of the American Diabetes Association, Galloway served two terms on its board of directors. In addition, he has been a member of the Therapeutics Committee, chaired the Insurance Committee, and a Task Force for Third-Party Payment for Diabetes Education for the ADA.

He served as President of the Indianapolis Diabetes Association, 1973–1974, and was co-founder of the American Diabetes Association, Indiana Affiliate.

Galloway taught at Indiana University School of Medicine where he was named Professor of Medicine in 1980. He became Professor Emeritus on Jan. 1, 1997.

Publications

He is the author or co-author of over 80 publications and 50 abstracts in the field of diabetes. He is also principal author and co-editor of the Eli Lilly publication, Diabetes Mellitus, Ninth Edition.

Awards

Patents

Related Research Articles

<span class="mw-page-title-main">Insulin</span> Peptide hormone

Insulin is a peptide hormone produced by beta cells of the pancreatic islets encoded in humans by the INS gene. It is considered to be the main anabolic hormone of the body. It regulates the metabolism of carbohydrates, fats and protein by promoting the absorption of glucose from the blood into liver, fat and skeletal muscle cells. In these tissues the absorbed glucose is converted into either glycogen via glycogenesis or fats (triglycerides) via lipogenesis, or, in the case of the liver, into both. Glucose production and secretion by the liver is strongly inhibited by high concentrations of insulin in the blood. Circulating insulin also affects the synthesis of proteins in a wide variety of tissues. It is therefore an anabolic hormone, promoting the conversion of small molecules in the blood into large molecules inside the cells. Low insulin levels in the blood have the opposite effect by promoting widespread catabolism, especially of reserve body fat.

<span class="mw-page-title-main">C-peptide</span> Chemical compound

The connecting peptide, or C-peptide, is a short 31-amino-acid polypeptide that connects insulin's A-chain to its B-chain in the proinsulin molecule. In the context of diabetes or hypoglycemia, a measurement of C-peptide blood serum levels can be used to distinguish between different conditions with similar clinical features.

<span class="mw-page-title-main">Eli Lilly and Company</span> American pharmaceutical company

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War.

<span class="mw-page-title-main">Indiana University School of Medicine</span> Medical school in the U.S. state of Indiana

The Indiana University School of Medicine (IUSM) is a major multi-campus medical school located in the US state of Indiana. There are nine campuses throughout the state; the principal research, educational, and medical center is located on the Indiana University–Purdue University Indianapolis (IUPUI) campus in Indianapolis. With 1,436 MD students and 200 PhD students in 2021, IUSM is one of the largest medical schools in the United States. The school offers many joint-degree programs including an MD-PhD Medical Scientist Training Program in a partnership with Purdue University's Weldon School of Biomedical Engineering. It is the medical school with the largest number of graduates licensed in the United States per a 2018 Federation of State Medical Boards survey with 11,828 licensed physicians.

<span class="mw-page-title-main">Tolbutamide</span> Chemical compound

Tolbutamide is a first-generation potassium channel blocker, sulfonylurea oral hypoglycemic medication. This drug may be used in the management of type 2 diabetes if diet alone is not effective. Tolbutamide stimulates the secretion of insulin by the pancreas.

<span class="mw-page-title-main">Eli Lilly</span> American pharmacist, Union Army officer, businessman, philanthropist

Eli Lilly was an American soldier, pharmacist, chemist, and businessman who founded the Eli Lilly and Company pharmaceutical corporation. Lilly enlisted in the Union Army during the American Civil War and recruited a company of men to serve with him in the 18th Independent Battery Indiana Light Artillery. He was later promoted to major and then colonel, and was given command of the 9th Regiment Indiana Cavalry. Lilly was captured in September 1864 and held as a prisoner of war until January 1865. After the war, he attempted to run a plantation in Mississippi, but it failed and he returned to his pharmacy profession after the death of his first wife. Lilly remarried and worked with business partners in several pharmacies in Indiana and Illinois before opening his own business in 1876 in Indianapolis. Lilly's company manufactured drugs and marketed them on a wholesale basis to pharmacies. Lilly's pharmaceutical firm proved to be successful and he soon became wealthy after making numerous advances in medicinal drug manufacturing. Two of the early advances he pioneered were creating gelatin capsules to contain medicines and developing fruit flavorings. Eli Lilly and Company became one of the first pharmaceutical firms of its kind to staff a dedicated research department and put into place numerous quality-assurance measures.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

<span class="mw-page-title-main">Drug development</span> Process of bringing a new pharmaceutical drug to the market

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process – from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials – to approved vaccine or drug typically takes more than a decade.

<span class="mw-page-title-main">Sidney & Lois Eskenazi Hospital</span> Hospital in Indinapolis, Indiana, U.S.

The Sidney & Lois Eskenazi Hospital is a public hospital located in Indianapolis, Indiana. The hospital is the flagship medical center for Eskenazi Health, founded in 1859 as Indiana's oldest public healthcare system. The hospital is operated by Health and Hospital Corporation of Marion County. The current hospital opened December 7, 2013, less than 1,300 feet (400 m) to the west of the original campus, replacing Wishard Memorial Hospital.

<span class="mw-page-title-main">Donald F. Steiner</span> American biochemist

Donald Frederick Steiner was an American biochemist and a professor at the University of Chicago.

Robert William Schrier was founding editor-in-chief of the magazine Nature Clinical Practice Nephrology. Schrier was formerly Chairman of the Department of Medicine at the University of Colorado School of Medicine for 26 years, and Head of the Division of Renal Diseases and Hypertension for 20 years. At the time of his death, he was Professor Emeritus at the University of Colorado School of Medicine. He died in Potomac, Maryland.

The Dr. Paul Janssen Award for Biomedical Research is given annually by Johnson & Johnson to honor the work of an active scientist in academia, industry or a scientific institute in the field of biomedical research. It was established in 2004 and perpetuates the memory of Paul Janssen, the founder of Janssen Pharmaceutica, a Johnson & Johnson subsidiary.

<span class="mw-page-title-main">James M. Galloway</span>

James M. Galloway is an American medical doctor and public health physician. Galloway served as the Regional Health Administrator for the United States Department of Health and Human Services for the six eastern states that comprise Region V under Presidents George W. Bush and Barack Obama. He also served as the Senior Federal Official for Health for Pandemic Influenza and Bioterrorism for the Department of Homeland Security's Region C, which includes an additional six states. Galloway was the lead for one of CDC's lead efforts as the Director of the Office of Health System Collaboration, integrating clinical care and public health at a national level.

<span class="mw-page-title-main">C. Ronald Kahn</span> American physician and scientist

Carl Ronald Kahn is an American physician and scientist, best known for his work with insulin receptors and insulin resistance in diabetes and obesity. He is the Chief Academic Officer at Joslin Diabetes Center, the Mary K. Iacocca Professor of Medicine at Harvard Medical School and a member of the National Academy of Sciences since 1999.

<span class="mw-page-title-main">Jose F. Caro</span> American physician

José F. Caro, M.D. is an American physician, scientist, and educator most notable for his research in obesity and diabetes. The Institute for Scientific Information listed him the third most cited investigator in the world in the field of obesity research during the 1991-2000 period for his work on Leptin. Caro is an artist and a signature member of the Pastel Society of America.

Harvey N. Middleton was a physician and cardiologist in Indianapolis, Indiana, who is best known for his efforts to open opportunities for black physicians to serve on the staffs of Indianapolis hospitals and for his community service. Middleton was born in Denmark, South Carolina, and received a Bachelor of Arts degree from Benedict College (1919) in Columbia, South Carolina. He attended two years of medical school at Boston University before transferring to Meharry Medical College, in Nashville, Tennessee, where he received a medical degree (M.D.) in 1926. Middleton took short courses for additional training at Harvard University; the University of London, England; the University of Michigan; Indiana University; and Michael Reese Hospital in Chicago. In 1928 Middleton moved to Anderson, Indiana, where he joined the staff of Saint Johns Hospital. Around 1935 he relocated to Indianapolis, established a private medical practice, and volunteered at Indianapolis General (City) Hospital's outpatient heart clinic. Middleton was accepted as a member of City Hospital staff in 1942 and joined the staffs at other Indianapolis hospitals. Middleton wrote several articles relating to cardiology that appear in state and national medical journals. He was a member of the American Medical Association, the National Medical Association, the American Heart Association, the Indiana State Medical Association, the Hoosier State Medical Society, and others.

Shashank R. Joshi is an Indian endocrinologist, diabetologist and medical researcher, considered by many as one of the prominent practitioners of the trade in India. He was honoured by the Government of India, in 2014, by bestowing on him the Padma Shri, the fourth highest civilian award, for his services to the field of medicine. He is a part of the COVID-19 Task Force for the state of Maharashtra, India.

<span class="mw-page-title-main">Daniel J. Drucker</span> Canadian endocrinologist

Daniel Joshua Drucker is a Canadian endocrinologist. A Fellow of the Royal Society, he is a professor of medicine at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto. He is known for his research into intestinal hormones and their use in the treatment of diabetes and other metabolic diseases.

Undurti Narasimha Das shortly Undurti N. Das and U. N. Das is an Indian clinical immunologist, endocrinologist and the founder president and chief executive officer of UND Life Sciences. Additionally, he serves as the Chief Medical Officer and the Chairman of the Scientific Advisory Board of Asha Nutrition Sciences, Inc. An elected fellow of the National Academy of Medical Sciences, Das is known for his researches in the fields of Immunology, Endocrinology and Rheumatology. He holds a number of patents for his work The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Medical Sciences in 1992.

Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.